We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In an effort to build opposition to the FDA’s proposed generic drug safety labeling rule, GPhA is warning that spending on generics will rise by $4 billion per year if the rule is finalized. Read More
Government auditors Monday criticized the FDA for its ongoing drug shortages problem, while House lawmakers chastised the agency at a hearing for not taking more action. Read More
Merck has agreed to pay $100 million to settle thousands of liability claims alleging the drugmaker’s NuvaRing contraceptive causes potentially fatal venous thromboembolisms. Read More
Just when things were starting to turn around for Teva, the Israeli drugmaker said Monday it was under federal investigation for potential marketing violations of its drugs Copaxone and Azilect. Read More
The Centers for Medicare and Medicaid Services (CMS) has relaxed the deadline for submitting 2013 data under the Physician Payment Sunshine Act, giving drugmakers until late spring to report the details of payment information. Read More
A new report from PricewaterhouseCoopers claims that value and volume of pharmaceutical mergers and acquisitions increased in the last quarter of 2013. Read More
The U.S. experienced 38 drug shortages during the first three quarters of 2013, a substantial drop from 2012 when 117 drug shortages were reported, according to FDA figures released Friday ahead of a scheduled House hearing on the issue. Read More
Gilead is yielding to pressure to reduce the price of its game-changing hepatitis C drug Sovaldi just weeks after it hit the U.S. market, developing an access program as well as licensing partnerships with generic drugmakers in India to manufacture cheaper versions of the drug for the Indian market. Read More
Days after the FDA said it plans to investigate the safety of testosterone replacement drugs, Abbott was hit with five lawsuits claiming the drugmaker marketed Androgel to millions of men who didn’t need it and hid the risks of heart attack and stroke associated with the drug. Read More
In an effort to build opposition to the FDA’s proposed generic drug safety labeling rule, GPhA is warning that spending on generics will rise by $4 billion per year if the rule is finalized. Read More